NASDAQ:HTBX - Heat Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 215.79 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.95
▼ -0.05 (-5.00%)
1 month | 3 months | 12 months
Get New Heat Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HTBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HTBX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.00
▲ +215.79% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Heat Biologics in the last 3 months. The average price target is $3.00, with a high forecast of $4.00 and a low forecast of $2.00. The average price target represents a 215.79% upside from the last price of $0.95.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Heat Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020B. RileyReiterated RatingBuyMedium
i
Rating by J. Zelin at B. Riley
10/14/2020B. RileyInitiated CoverageBuy$4.00 ➝ $4.00Low
i
6/19/2020Maxim GroupInitiated CoverageBuy$2.00Low
i
Rating by Jason McCarthy at Maxim Group
5/15/2020Maxim GroupInitiated CoverageBuy$2.00Low
i
Rating by Jason McCarthy at Maxim Group
4/1/2020Maxim GroupReiterated RatingBuy$2.00Medium
i
3/5/2020Maxim GroupBoost Price Target$1.00 ➝ $2.00High
i
3/3/2020Maxim GroupReiterated RatingBuy$1.00High
i
2/6/2020Maxim GroupInitiated CoverageBuyHigh
i
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$8.00 ➝ $8.00High
i
Rating by K. Raja at Brookline Capital Management
5/17/2019Alliance Global PartnersSet Price TargetBuy$6.00Medium
i
Rating by James Molloy at Alliance Global Partners
11/16/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/1/2018Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by K. Raja at Brookline Capital Management
7/9/2018Eurobank EFGInitiated CoverageBuy$11.00High
i
Rating by James Molloy at Eurobank EFG
6/26/2018HC WainwrightInitiated CoverageBuy$6.00High
i
Rating by J. Pantginis at HC Wainwright
9/12/2017Griffin SecuritiesInitiated CoverageBuy$22.50High
i
Rating by K. Markey at Griffin Securities
7/4/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
5/14/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Mark Jordan at Noble Financial
4/6/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
3/23/2017Noble FinancialReiterated RatingBuyHigh
i
3/13/2017Noble FinancialReiterated RatingBuyHigh
i
12/8/2016Roth CapitalSet Price TargetBuy$20.00N/A
i
Rating by Joseph Pantginis at Roth Capital
12/1/2016Roth CapitalSet Price TargetBuy$27.50 ➝ $20.00N/A
i
Rating by Joseph Pantginis at Roth Capital
9/15/2016Roth CapitalReiterated RatingBuy$27.50N/A
i
Rating by Joseph Pantginis at Roth Capital
8/17/2016Noble FinancialReiterated RatingBuy$80.00N/A
i
8/17/2016Roth CapitalReiterated RatingBuy$27.50N/A
i
Rating by Joseph Pantginis at Roth Capital
6/20/2016Roth CapitalInitiated CoverageBuy$27.50N/A
i
Rating by J. Pantginis at Roth Capital
4/9/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
2/21/2016HC WainwrightReiterated RatingBuy$130.00N/A
i
Rating by Mark Breidenbach at HC Wainwright
2/19/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
2/11/2016Noble FinancialReiterated RatingBuy$160.00N/A
i
Rating by Rahul Jasuja at Noble Financial
2/1/2016HC WainwrightReiterated RatingBuy$130.00N/A
i
Rating by Mark Breidenbach at HC Wainwright
1/8/2016Noble FinancialInitiated CoverageBuy$160.00N/A
i
(Data available from 11/25/2015 forward)
Heat Biologics logo
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $0.95
$0.93
$0.98

50 Day Range

MA: $1.16
$1.00
$1.37

52 Week Range

Now: $0.95
$0.20
$4.30

Volume

7,545,427 shs

Average Volume

15,913,941 shs

Market Capitalization

$151.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57